House of Cures

The Health Care Blog

Home

Syndication

RSS for Posts
Atom
RSS for Comments

Archives

March 2019 (15)
February 2019 (24)
January 2019 (24)
December 2018 (26)
November 2018 (26)
October 2018 (32)
September 2018 (23)
August 2018 (26)
July 2018 (29)
June 2018 (28)
May 2018 (27)
April 2018 (37)
March 2018 (46)
February 2018 (31)
January 2018 (33)
December 2017 (33)
November 2017 (27)
October 2017 (29)
September 2017 (36)
August 2017 (25)
July 2017 (32)
June 2017 (31)
May 2017 (41)
April 2017 (40)
March 2017 (61)
February 2017 (45)
January 2017 (39)
December 2016 (34)
November 2016 (43)
October 2016 (42)
September 2016 (36)
August 2016 (44)
July 2016 (33)
June 2016 (41)
May 2016 (39)
April 2016 (12)
March 2016 (33)
February 2016 (50)
January 2016 (50)
December 2015 (48)
November 2015 (41)
October 2015 (65)
September 2015 (52)
August 2015 (49)
July 2015 (55)
June 2015 (60)
May 2015 (43)
April 2015 (13)
March 2015 (29)
February 2015 (44)
January 2015 (52)
December 2014 (60)
November 2014 (31)
June 2011 (28)
May 2011 (79)
April 2011 (109)
March 2011 (87)
February 2011 (84)
January 2011 (103)
December 2010 (74)
November 2010 (84)
October 2010 (63)
September 2010 (70)
August 2010 (67)
July 2010 (82)
June 2010 (78)
May 2010 (64)
April 2010 (53)
March 2010 (83)
February 2010 (63)
January 2010 (50)
December 2009 (47)
November 2009 (54)
October 2009 (72)
September 2009 (4)

By STEVE FINDLAY Lawmakers in Washington are gearing up to pass major, far-reaching legislation on drug approval and cancer research. This is a good thing in the main but—no surprise here—Republicans and Democrats differ on approach and details, and things Read More...

Read the complete post at http://thehealthcareblog.com/blog/2016/02/06/house-of-cures/

Posted Feb 05 2016, 11:19 PM by THCB

Filed under: THCB, Steven Findlay

House of Cures

Syndication

Recent Posts

Tags

Archives